Purchase

Recombinant Human CCL3 protein (rFc Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg3309


Product Information

Purity >90 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Not tested
Expression CHO-derived Human CCL3 protein Ser24-Ala92 (Accession# P10147) with a rabbit IgG Fc tag at the C-terminus.
GeneID 6348
Accession P10147
PredictedSize 33.7 kDa
SDS-PAGE 35-39 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in 30mM Tris,500mM arginine, pH 8.0. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

CCL3, also known as macrophage inflammatory protein-1 alpha (MIP-1α), belongs to the CC chemokine family and is a small-molecule cytokine secreted by activated immune cells such as T cells and macrophages. Its primary function is to bind to and activate the chemokine receptors CCR1 and CCR5 on cell surfaces, thereby recruiting and activating various immune cells including monocytes, macrophages, T cells, and dendritic cells. This plays a critical role in infection defense, inflammatory responses, and tumor immune surveillance. Research indicates that CCL3 is aberrantly expressed in conditions such as rheumatoid arthritis, HIV infection, and the microenvironment of various tumors, making it an important therapeutic target for inflammatory diseases and tumor immunotherapy. Receptor antagonists targeting its pathway, such as anti-CCR5 drugs, have already been applied in clinical practice.

References:

1. Soares, Denis Melo et al. Brain research vol. 1269 (2009): 54-60. 2. Barcelos, Lucíola S et al. Microvascular research vol. 78,2 (2009): 148-54. 3. Yang, Ying-Li et al. Rheumatology and therapy vol. 10,4 (2023): 793-808. 4. Ntanasis-Stathopoulos, Ioannis et al. Advances in experimental medicine and biology vol. 1231 (2020): 13-21.


||
New chat

Able

正在加载,请稍候...